FDA grants accelerated approval to the combination of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer
- Trial
- RAMP 201
- Drug
- Avmapki Fakzynja Co-pack (avutometinib and defactinib) · Multi-ingredient
- Condition
- Gynecologic